Clinical Trials In Pulmonary Arterial Hypertension

Detailing state-of-the-art developments in the various aspects of primary pulmonary hypertension (PPH), this practical reference explores the history, most current scientific concepts, and treatments of this disease. Includes new advances not yet formally published! Written by nearly 30 of the top international experts in the field, Primary Pulmonary Hypertension addresses the general histological features of the normal and hypertensive pulmonary vasculature and the pathology of PPH discusses etiological possibilities of pathogenesis, common morphological features, and findings in experimental models examines risks factors for PPH and looks separately at familial PPH and PPH in children presents an approach to the differential diagnosis of pulmonary hypertension, emphasizing the recognition of PPH elucidates the invasive and noninvasive modalities available for obtaining qualitative and quantitative hemodynamic data for the diagnosis of PPH covers a variety of therapeutic options and much more!

Written by internationally recognized experts, Pulmonary Hypertension bridges the gap between pulmonology and cardiology to provide clinicians in both disciplines with knowledge of the signs, symptoms, diagnosis, and pharmacologic and surgical treatments for pulmonary hypertension (PH). Through the use of clinical trials, this ground-breaking text

First book dedicated to this disease, previously thought to be incurable, but with the advent of new drugs, now amenable to management and a much improved prognosis for patients From the PAH Association, the leading experts in field Incorporates the latest AACP management guidelines Includes evidence-based treatment algorithms based on the recently updated ACCP Guidelines for Medical Treatment Aimed at specialists in pulmonology and cardiovascular disease, this volume provides the clinician with the most up to date information on the effective management of PAH

This open access book focuses on the molecular mechanism of congenital heart disease and pulmonary hypertension, offering new insights into the development of pulmonary circulation and the ductus arteriosus. It describes in detail the molecular mechanisms involved in the development and morphogenesis of the heart, lungs and ductus arteriosus, covering a range of topics such as gene functions, growth factors, transcription factors and cellular interactions, as well as stem cell engineering technologies. The book also presents recent advances in our understanding of the molecular mechanism of lung development, pulmonary hypertension and molecular regulation of the ductus arteriosus. As such, it is an ideal resource for physicians, scientists and investigators interested in the latest findings on the origins of congenital heart disease and potential future therapies involving pulmonary circulation/hypertension and the ductus arteriosus.

Internationally renowned authorities from diverse fields present the principles and practice regarding the measurement of drug effects in humans and its role in the analysis and development of new chemical entities. The main thrust is on surrogate endpoints, peripheral vascular disease, the reliability of data collection and interpretation as well as the identification, predictability and performance of drug interactions and adverse effects.

Pulmonary arterial hypertension (PAH) is a high blood pressure in the arteries that supply the lungs with blood. Patients with mild PAH, particularly young patients, may feel quite well and get breathless or tired only with vigorous exertion. Those with severe PAH may get breathless on minimal exertion and feel tired, exhausted and experience chest pain, forceful heart beats, dizzy turns, loss of appetite, and have swelling of the legs due to fluid retention. This book will help patients and their families understand what PAH is, and advise them on how to cope with their illness. In the UK patients with PAH are referred to one of the eight National Pulmonary Hypertension centres staffed by a team of specialist doctors, nurses, pharmacists, and other staff who are experienced and expert in managing all aspects of the condition. Currently, the drugs used to treat the condition can be prescribed only by these specialists. The book will explain what the illness is and how it is treated in a reassuring and understandable way. The book will also be of interest to GPs, nurses and other related healthcare professionals.

Pulmonary hypertension (PH) is increased pressure in the pulmonary arteries, which carry blood from the heart to the lungs to pick up oxygen. The changes resulting from PH make it difficult for the heart to push blood through the pulmonary arteries, causing the heart to become weak and possibly to develop failure. Understanding the causes and treatment of PH can help heart failure specialists prevent heart failure due to PH.

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.